Alessio Cantore

Group Leader

San Raffaele Telethon Institute for Gene Therapy
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

The efficacy of hemophilia B (HB) replacement therapy is evaluated by coagulation factor IX (FIX) activity in plasma, although FIX bound to extravascular type IV collagen (Col4) also contributes to efficient hemostasis. Here, we investigated the impact of engineering FIX for improved (K5R) or reduced (K5A) Col4 binding on the pharmacokinetic properties of FIX Padua, fused to human serum albumin (HSA QMP ) engineered for favorable neonatal Fc receptor (FcRn) engagement. Hyperactive features and extended plasma half-life in human FcRn expressing mice, attributed to FIX Padua and HSA QMP engineering, respectively, was confirmed. In HB mice, Padua KA -HSA QMP exhibited negligible extravascular distribution and the highest plasma levels at early time points followed by the steepest decay. Conversely, Padua KR -HSA QMP showed increased extravascular distribution and a 3-fold longer functional half-life (80 hours). These findings support the use of Padua KA -HSA QMP and Padua KR -HSA QMP as hyperactive short- or long-term therapeutics, respectively, with opportunities for tailored HB replacement therapy.

Year:

2025

Year:

2025

Year:

2025

The liver is an essential organ of the body that performs several vital functions, including the metabolism of biomolecules, foreign substances, and toxins, and the production of plasma proteins, such as coagulation factors. There are hundreds of genetic disorders affecting liver functions and, for many of them, the only curative option is orthotopic liver transplantation, which nevertheless entails many risks and long-term complications. Some peculiar features of the liver, such as its large blood flow supply and the tolerogenic immune environment, make it an attractive target for in vivo gene therapy approaches. In recent years, several genome-editing tools mainly based on the clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9) system have been successfully exploited in the context of liver-directed preclinical or clinical therapeutic applications. These include gene knock-out, knock-in, activation, interference, or base and prime editing approaches. Despite many achievements, important challenges still need to be addressed to broaden clinical applications, such as the optimization of the delivery methods, the improvement of the editing efficiency, and the risk of on-target or off-target unwanted effects and chromosomal rearrangements. In this review, we highlight the latest progress in the development of in vivo liver-targeted genome editing approaches for the treatment of genetic disorders. We describe the technological advancements that are currently under investigation, the challenges to overcome for clinical applicability, and the future perspectives of this technology.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (12)

Antonella Forlino

University of Pavia

ITALY
View details

Chiara Brombin

Assistant Professor in Statistics SECS-S/01 (RTD-B)

Università Vita Salute San Raffaele

ITALY
View details

Valentina Capo

Staff Scientist

San Raffaele Telethon Institute for Gene Therapy

ITALY
View details

Matteo Iannacone

Director

Vita-Salute San Raffaele University

ITALY
View details

Carmen Unzu

Principal Investigator

Center for Applied Medical Research

SPAIN
View details

Davide Mazza

Deputy Director

Ospedale San Raffaele

ITALY
View details

Giuseppe Ronzitti

Researcher

INSERM

FRANCE
View details

Giuseppe Valacchi

David Murdock Distinguished Professor

North Carolina State University

UNITED STATES
View details

Samuel Zambrano

Vita-Salute San Raffaele University

ITALY
View details

Elena Barbon

San Raffaele Telethon Institute for Gene Therapy

ITALY
View details

Stefano Beretta

San Raffaele Telethon Institute for Gene Therapy

ITALY
View details

Alessio Branchini

Senior Assistant Professor of Molecular Biology

University of Ferrara

ITALY
View details